MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
$435,344K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Net income
Accrued expenses and other payab...
Share-based compensation expense...
Others
Negative Cash Flow Breakdown
Accounts receivable
Inventories
Amortization of research and dev...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net income
237,007
227,357
66,502
124,841
Depreciation and amortization expense
40,515
41,144
35,984
37,284
Share-based compensation expenses
137,405
123,355
123,761
140,809
Acquired in-process research and development
20,518
-
0
191
Amortization of research and development cost share liability
-29,518
-28,645
-26,251
-29,275
Impairment of equity investments
-
-
75,626
-
Loss on long-term investments
-
-
-596
-
Non-cash interest expense
-
-
14,872
-
Deferred income tax expense
-
-
9,469
-
Impairment of equity investments
-
-
-
34,216
Gain on bms termination settlement
-
-
0
-
Non-cash interest expense
-
21,096
-
-
Other items, net
8,240
6,172
-12,548
-5,533
Accounts receivable
117,576
75,300
-2,340
93,925
Inventories
47,150
71,838
70,506
28,836
Other assets
11,377
-15,270
18,083
-100,563
Accounts payable
37,530
-42,187
87,214
28,471
Accrued expenses and other payables
212,435
-16,819
145,876
90,261
Deferred revenue
-
-
1,293
-
Other liabilities
-4,113
1,731
15,418
3,486
Net cash provided by operating activities
462,820
201,336
417,347
402,553
Purchases of property, plant and equipment
27,476
40,789
37,522
48,084
Purchase of intangible assets
0
-
0
0
Purchase of long-term investments
-
-
11,834
-
Proceeds from sale or maturity of short-term investments
-
-
1,646
0
Proceeds from sale or maturity of investments
5,845
27
-
-
Purchase of in-process research and development
20,518
0
0
691
Other investing activities
7,204
4,748
-9,375
499
Net cash used in investing activities
-49,353
-45,510
-38,335
-49,274
Proceeds from sale of future royalties
-
-
26,000
885,000
Proceeds from long-term loan
-
-
850,586
0
Repayment of long-term loan
17,052
7,641
14,618
4,263
Proceeds from short-term loans
0
58,204
12,155
0
Repayment of short-term loans
0
0
768,999
0
Payments of debt issuance costs
-
-
23,392
-
Repayment of sale of future royalties liability
-1
2,557
4,044
-
Payments of withholding taxes from share-based awards
0
-
0
0
Proceeds from option exercises and employee share purchase plan
11,048
23,875
19,243
80,535
Other financing activities
-51
-3,249
0
0
Net cash provided by financing activities
-6,054
68,632
96,931
961,272
Effect of foreign exchange rate changes, net
19,836
19,320
23,162
9,905
Net increase in cash, cash equivalents, and restricted cash
427,249
243,778
499,105
1,324,456
Cash, cash equivalents, and restricted cash at beginning of period
4,853,425
4,609,647
4,110,542
2,638,747
Cash, cash equivalents, and restricted cash at end of period
5,280,674
4,853,425
4,609,647
4,110,542
Cash and cash equivalents
5,098,041
-
-
-
Short-term restricted cash
161,046
-
-
-
Long-term restricted cash
21,587
-
-
-
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Net income
$237,007K
(147.94%↑ Y/Y)
Accrued expenses and
other payables
$212,435K
(180.91%↑ Y/Y)
Share-based compensation
expenses
$137,405K
(-44.21%↓ Y/Y)
Depreciation and
amortization expense
$40,515K
(-40.78%↓ Y/Y)
Accounts payable
$37,530K
(204.68%↑ Y/Y)
Acquired in-process
research and development
$20,518K
(4003.60%↑ Y/Y)
Net cash provided by
operating activities
$462,820K
(50.42%↑ Y/Y)
Effect of foreign
exchange rate changes,...
$19,836K
(-26.42%↓ Y/Y)
Canceled cashflow
$209,734K
Net increase in
cash, cash...
$427,249K
(189.98%↑ Y/Y)
Canceled cashflow
$55,407K
Accounts receivable
$117,576K
(60.25%↑ Y/Y)
Inventories
$47,150K
(863.69%↑ Y/Y)
Amortization of research and
development cost share...
-$29,518K
(35.22%↑ Y/Y)
Other assets
$11,377K
(-74.89%↓ Y/Y)
Other liabilities
-$4,113K
(-6526.56%↓ Y/Y)
Proceeds from sale or
maturity of investments
$5,845K
(224.72%↑ Y/Y)
Proceeds from option
exercises and employee...
$11,048K
(-88.55%↓ Y/Y)
Repayment of sale of future
royalties liability
-$1K
Net cash used in
investing activities
-$49,353K
(73.82%↑ Y/Y)
Net cash provided by
financing activities
-$6,054K
(-585.10%↓ Y/Y)
Canceled cashflow
$5,845K
Canceled cashflow
$11,049K
Purchases of property,
plant and equipment
$27,476K
(-72.59%↓ Y/Y)
Purchase of in-process
research and development
$20,518K
(-65.80%↓ Y/Y)
Other investing
activities
$7,204K
(-28.76%↓ Y/Y)
Repayment of long-term
loan
$17,052K
(1.51%↑ Y/Y)
Other financing
activities
-$51K
Buy us a coffee
BeOne Medicines Ltd. (BEIGF)
BeOne Medicines Ltd. (BEIGF)